Mr. Hastings has served as president and chief executive officer of OncoMed Pharmaceuticals since January 2006. Prior to joining OncoMed, Mr. Hastings was president and chief executive officer of QLT, Inc. Before this role, Mr. Hastings served as president and chief executive officer of Axys Pharmaceuticals, which was acquired by Celera Corporation in 2001. Prior to Axys, Mr. Hastings was president of Chiron Biopharmaceuticals and also held a variety of management positions of increasing responsibility at Genzyme Corporation, including president of Genzyme Therapeutics Europe and president of Worldwide Therapeutics. Mr. Hastings currently serves as chairman of the board of the Bay Area Biosciences Association (Bay Bio) and serves on the executive committee of the board of directors of the Biotechnology Industry Association. He received a Bachelor of Science degree in pharmacy from the University of Rhode Island.
"With our recent initial public offering and our new drug application submission to the Food and Drug Administration, we have entered a new phase of development as a company," said Fred Middleton, chairman of the board of Pacira Pharmaceuticals. "We are pleased to attr
|SOURCE Pacira Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved